AI drug firm Pathos raises $237M, valuation hits $3B in BMS-linked deal

Pathos, an AI-driven drug discovery company, raised $237 million, bringing its valuation to $3 billion. The deal combines Tempus's large dataset, Pathos's AI analysis, and Bristol Myers Squibb's drug development capabilities, signaling continued investor appetite for AI in pharma. The funding round underscores the strategic integration of AI and biotech, though the specific therapeutic focus and clinical milestones remain undisclosed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works